Breaking News Instant updates and real-time market news.

EPZM

Epizyme

$15.25

-0.65 (-4.09%)

16:46
04/23/18
04/23
16:46
04/23/18
16:46

Epizyme places a Hold on Tazemetostat Clinical Program enrollment

Epizyme announced that U.S.-based enrollment of new patients into tazemetostat clinical trials is temporarily on hold. Following a safety report of a pediatric patient who developed a secondary lymphoma, the U.S. Food and Drug Administration issued a partial clinical hold affecting new enrollment of patients with genetically defined solid tumors and hematologic malignancies, while the company updates the informed consent, investigator's brochure and study protocols. Patients on study who have not experienced disease progression may continue to receive tazemetostat. Epizyme has begun developing the modifications to address the partial clinical hold, and will need to confirm alignment with the FDA in order to resume U.S. enrollment. The partial clinical hold was initiated following a safety report, submitted by Epizyme to the FDA and other regulatory authorities, regarding a patient with advanced poorly differentiated chordoma in the company's Phase 1 pediatric study who developed a secondary T-cell lymphoma. Doses explored in this study are higher than those in the company's Phase 2 adult studies, an approach not uncommon to drug development in aggressive, difficult-to-treat pediatric cancers. At the time of the safety report, the patient had been on study for approximately 15 months and had achieved a confirmed partial response. This patient has now discontinued tazemetostat and is being treated for T-cell lymphoma. Secondary malignancies are known to be potential adverse events associated with many cancer therapies, including chemotherapy and radiation treatment. T-cell lymphoma has been identified as a potential adverse event in tazemetostat study protocols and is included in the investigator's brochure and the informed consent. More than 750 patients have been treated with tazemetostat to date, and this is the only case of secondary lymphoma that has been observed across the tazemetostat clinical program.

  • 25

    Apr

EPZM Epizyme
$15.25

-0.65 (-4.09%)

02/01/18
ROTH
02/01/18
INITIATION
Target $24
ROTH
Buy
Epizyme initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Epizyme with a Buy rating and $24 price target as he believes its lead agent tazemetostat, an inhibitor of the histone methyltrasferase EZH2, has laid out a sufficiently wide clinical footprint, and is sufficiently close to an NDA in several indications, that even his conservative approach of ranking its clinical programs shows that the company still remains undervalued.
02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/14/18
RHCO
03/14/18
NO CHANGE
Target $27
RHCO
Buy
Epizyme price target raised to $27 from $21 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Epizyme to $27, saying the company's Q4 earnings call reiterated expectations of on-track data flow in epithelioid sarcoma registrations / NDA filing later this year, the combo data for DLBCL, and the follicular lymphoma data and registration path in the second half of 2018. Lawson keeps his Buy rating and attributes his price target revision to the treatment's higher probability of success.
04/11/18
JEFF
04/11/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme recent pullback creates attractive risk/reward, says Jefferies
Jefferies analyst Michael Yee believes the recent pullback in shares of Epizyme creates an attractive risk/reward ahead of a "catalyst-rich" 2018. The company's market capitalization could appreciate from less than $1B to $2-$3B over time if data in the second half "starts to play out like we expect," Yee tells investors in a research note. He thinks Epizyme's mixed shelf filing last week has some investors concerned that an equity financing could be possible in the near term. Yee believes, however, that the filing "simply replaces and refreshes" an existing one that has always been on hand as opposed to suggesting the company is getting ready to raise near-term cash. The analyst keeps a Buy rating on the shares with a $27 price target.

TODAY'S FREE FLY STORIES

KKR

KKR

$28.12

-0.13 (-0.46%)

21:13
09/25/18
09/25
21:13
09/25/18
21:13
Hot Stocks
KKR forms management company to provide health care services in China »

KKR announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

A

Agilent

$70.38

0.43 (0.61%)

21:11
09/25/18
09/25
21:11
09/25/18
21:11
Hot Stocks
Agilent acquires ACEA Bioscience for $250M in cash »

Agilent Technologie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

EQM

EQT Midstream Partners

$52.64

-2.16 (-3.94%)

20:58
09/25/18
09/25
20:58
09/25/18
20:58
Recommendations
EQT Midstream Partners analyst commentary  »

EQT Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPAY

FlexShopper

$1.16

-0.69 (-37.30%)

20:42
09/25/18
09/25
20:42
09/25/18
20:42
Syndicate
FlexShopper 10M unit Secondary priced at $1.00 »

acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

IGC

IGC, Inc

$2.32

-0.22 (-8.66%)

20:40
09/25/18
09/25
20:40
09/25/18
20:40
Hot Stocks
IGC to enter Hemp/CBD-infused energy drink space »

India Globalization…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$57.10

-0.33 (-0.57%)

20:32
09/25/18
09/25
20:32
09/25/18
20:32
Periodicals
Breaking Periodicals news story on Delta Air Lines »

Delta Air Lines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

SPY

SPDR S&P 500 ETF Trust

$290.73

-0.36 (-0.12%)

, SPX

S&P 500

$0.00

(0.00%)

20:32
09/25/18
09/25
20:32
09/25/18
20:32
Periodicals
Trump considering keeping Deputy AG Rosenstein, WSJ says »

Donald Trump has…

SPY

SPDR S&P 500 ETF Trust

$290.73

-0.36 (-0.12%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCE

Arco Platform

$0.00

(0.00%)

20:31
09/25/18
09/25
20:31
09/25/18
20:31
Syndicate
Arco Platform 11.111M share IPO priced at $17.50 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

KMX

CarMax

$75.87

-0.01 (-0.01%)

20:25
09/25/18
09/25
20:25
09/25/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 06

    Nov

AINC

Ashford

$75.95

-11.75 (-13.40%)

20:23
09/25/18
09/25
20:23
09/25/18
20:23
Syndicate
Ashford 270K share Secondary priced at $74.50 »

UBS, RBC Capital and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 26

    Sep

ANAB

AnaptysBio

$94.68

-7.25 (-7.11%)

20:21
09/25/18
09/25
20:21
09/25/18
20:21
Syndicate
AnaptysBio 2.2M share Secondary priced at $94.46 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SF

Stifel Financial

$53.96

-0.08 (-0.15%)

20:01
09/25/18
09/25
20:01
09/25/18
20:01
Hot Stocks
Stifel Financial and Everbright Sun Hung Kai establish strategic partnership »

Stifel Financial and Hong…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

I

Intelsat

$27.08

4.365 (19.22%)

19:59
09/25/18
09/25
19:59
09/25/18
19:59
Hot Stocks
Intelsat and Azercosmos announce successful satellite launch »

Intelsat S.A. and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKY

Skyline

$30.88

0.66 (2.18%)

19:49
09/25/18
09/25
19:49
09/25/18
19:49
Hot Stocks
Breaking Hot Stocks news story on Skyline »

Centerbridge Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

KBH

KB Home

$25.29

-0.24 (-0.94%)

, AIR

AAR Corp.

$46.03

1.04 (2.31%)

19:28
09/25/18
09/25
19:28
09/25/18
19:28
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: KB…

KBH

KB Home

$25.29

-0.24 (-0.94%)

AIR

AAR Corp.

$46.03

1.04 (2.31%)

VSTM

Verastem

$7.15

-1.74 (-19.57%)

CGIX

Cancer Genetics

$1.22

-0.01 (-0.81%)

VNDA

Vanda Pharmaceuticals

$20.70

0.3 (1.47%)

NLSN

Nielsen

$27.21

0.055 (0.20%)

CYH

Community Health

$3.41

-0.08 (-2.29%)

AUPH

Aurinia Pharmaceuticals

$5.89

0.02 (0.34%)

GOOS

Canada Goose

$58.00

-0.04 (-0.07%)

ABBV

AbbVie

$93.78

0.34 (0.36%)

NKE

Nike

$84.79

0.52 (0.62%)

CTAS

Cintas

$212.99

1.81 (0.86%)

LULU

Lululemon

$158.42

1.04 (0.66%)

CONE

CyrusOne

$64.65

-0.6 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 04

    Oct

  • 05

    Oct

  • 26

    Sep

CBS

CBS

$56.54

-0.07 (-0.12%)

19:19
09/25/18
09/25
19:19
09/25/18
19:19
Hot Stocks
CBS names Richard Parsons interim chairman »

Richard Parsons has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ZUMZ

Zumiez

$27.00

-0.55 (-2.00%)

19:09
09/25/18
09/25
19:09
09/25/18
19:09
Initiation
Zumiez initiated at DA Davidson »

Zumiez initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROST

Ross Stores

$97.54

0.26 (0.27%)

, TJX

TJX

$110.33

0.605 (0.55%)

19:03
09/25/18
09/25
19:03
09/25/18
19:03
Initiation
Ross Stores, TJX initiated at DA Davidson »

Ross Stores initiated…

ROST

Ross Stores

$97.54

0.26 (0.27%)

TJX

TJX

$110.33

0.605 (0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MNOV

MediciNova

$11.68

-0.17 (-1.43%)

19:01
09/25/18
09/25
19:01
09/25/18
19:01
Hot Stocks
MediciNova announces 'positive' FDA feedback on Phase 3 plan for MN-166 »

MediciNova announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$140.00

-0.56 (-0.40%)

18:58
09/25/18
09/25
18:58
09/25/18
18:58
Initiation
PVH Corp. initiated at DA Davidson »

PVH Corp. initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 03

    Oct

GOOS

Canada Goose

$58.00

-0.04 (-0.07%)

18:50
09/25/18
09/25
18:50
09/25/18
18:50
Initiation
Canada Goose initiated at DA Davidson »

Canada Goose initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.91

-0.55 (-0.68%)

18:47
09/25/18
09/25
18:47
09/25/18
18:47
Periodicals
Philip Morris hits streets to sell older smokers on new devices, Bloomberg says »

Philip Morris is moving a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 28

    Sep

URBN

Urban Outfitters

$40.06

-0.32 (-0.79%)

18:45
09/25/18
09/25
18:45
09/25/18
18:45
Initiation
Urban Outfitters initiated at DA Davidson »

Urban Outfitters…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

SVMK

SurveyMonkey

$0.00

(0.00%)

18:35
09/25/18
09/25
18:35
09/25/18
18:35
Syndicate
SurveyMonkey 15M share IPO priced at $12.00 »

The shares are expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

LULU

Lululemon

$158.42

1.04 (0.66%)

18:34
09/25/18
09/25
18:34
09/25/18
18:34
Initiation
Lululemon initiated at DA Davidson »

Lululemon initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.